Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7086181 | 0.92 | HMGCR (0.85) | HMGCR | |
| SCHEMBL7084466 | 0.85 | HMGCR (0.74) | HMGCR | |
| SCHEMBL1704691 | 0.82 | HMGCR (1.00) | HMGCR | |
| SCHEMBL7083916 | 0.80 | HMGCR (0.80) | HMGCR | |
| SCHEMBL6370947 | 0.80 | HMGCR (0.66) | HMGCR | |
| SCHEMBL911617 | 0.79 | HMGCR (0.65) | HMGCR | |
| SCHEMBL10426639 | 0.79 | HMGCR (0.65) | HMGCR | |
| SCHEMBL7083289 | 0.79 | HMGCR (0.65) | HMGCR | |
| SCHEMBL7134552 | 0.78 | HMGCR (0.76) | HMGCR | |
| SCHEMBL5662499 | 0.78 | HMGCR (0.63) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050232891-A1 | Methods of treating skin with diphosphonate derivatives | ILEX PRODUCTS INC. | 2005-10-20 | — | — | US | claimed |
| EP-1435970-A4 | METHODS OF TREATING SKIN WITH DIPHOSPHONATE DERIVATIVES | ILEX PRODUCTS INC (US) | 2005-05-04 | — | — | EP | claimed |
| EP-1435970-A2 | METHODS OF TREATING SKIN WITH DIPHOSPHONATE DERIVATIVES | Ilex Products, Inc. (US) | 2004-07-14 | — | — | EP | claimed |
| EP-1326618-A2 | USE OF ARYL-SUBSTITUTED 1,1-DIPHOSPHONATES FOR THE TREATMENT OF BONE DISEASES | Ilex Oncology Research S.A. (CH) | 2003-07-16 | — | — | EP | claimed |
| WO-2003032909-A2 | METHODS OF TREATING SKIN WITH DIPHOSPHONATE DERIVATIVES | ILEX PRODUCTS, INC. (US) | 2003-04-24 | — | — | WO | claimed |
| EP-0888365-B1 | A process for the preparation of diphosphonate derivatives | SYMPHAR SA (CH) | 2002-05-08 | — | — | EP | claimed |
| WO-2002011704-A2 | USE OF ARYL-SUBSTITUTED 1,1-DIPHOSPHONATES FOR THE TREATMENT OF BONE DISEASES | SYMPHAR S.A. (CH) | 2002-02-14 | — | — | WO | claimed |
| EP-0845991-B1 | USE OF PHENOL SUBSTITUTED DIPHOSPHONATES AS ANTINEOPLASTIC AGENTS | SYMPHAR SA (CH) | 2002-02-06 | — | — | EP | claimed |
| US-6127350-A | FOR TREATMENT AND PREVENTION OF RAS ONCOGENE DEPENDENT CANCERS AND METASTATIC INVASIONS | SYMPHAR S.A. (SE) | 2000-10-03 | — | — | US | claimed |
| US-6048995-A | Process for the preparation of diphosphonate derivatives | SYMPHAR S.A. (CH) | 2000-04-11 | — | — | US | claimed |
| EP-0845991-A2 | USE OF PHENOL SUBSTITUTED DIPHOSPHONATES AS ANTINEOPLASTIC AGENTS | SYMPHAR S.A. (CH) | 1998-06-10 | — | — | EP | claimed |
| WO-1997004785-A1 | USE OF PHENOL SUBSTITUTED DIPHOSPHONATES AS ANTINEOPLASTIC AGENTS | SYMPHAR S.A. (CH) | 1997-02-13 | — | — | WO | claimed |
| EP-0339237-B1 | PHENOL SUBSTITUTED GEM-DIPHOSPHONATE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYMPHAR S.A. (CH) | 1992-12-30 | — | — | EP | claimed |
| US-20240317751-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-09-26 | — | — | US | disclosed |
| EP-4306524-A2 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | PureTech LYT, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20220177474-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-09 | — | — | US | disclosed |
| EP-0888365-B1 | A process for the preparation of diphosphonate derivatives | SYMPHAR SA (CH) | 2002-05-08 | — | — | EP | disclosed |
| US-6048995-A | Process for the preparation of diphosphonate derivatives | SYMPHAR S.A. (CH) | 2000-04-11 | — | — | US | disclosed |
| US-5153183-A | Antiarthritic agents | TORAY INDUSTRIES, INC. (JP) | 1992-10-06 | — | — | US | disclosed |
| EP-0440809-A1 | METHYLENEDIPHOSPHONIC ACID COMPOUND AND ANTI-INFLAMMATORY CONTAINING THE SAME AS ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177474-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | BTK, P2RY1, P2RY13 | HMGCR 4754/4885 |
| US-20240317751-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | BTK, P2RY1, P2RY13 | HMGCR 4754/4885 |
| US-20050232891-A1 | Methods of treating skin with diphosphonate derivatives | COL1A1, COL2A1, COL14A1 | HMGCR 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.